Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real-World Cohort of 77 Patients.

Additionally, our study revealed that MG patients without thymoma demonstrated superior clinical responses to efgartigimod therapy compared to thymoma‐associated MG cases, although the intergroup difference did not reach statistical significance.

also in 111,027 other papers